WORLD JOURNAL OF GASTROENTEROLOGY世界胃肠病学杂志
WORLD JOURNAL OF GASTROENTEROLOGY(英文缩写 WORLD J GASTROENTERO),ISSN 1007-9327,eISSN 2219-2840,中文译名:世界胃肠病学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 5.374 | Q2 |
| 2022 | 4.300 | Q2 |
| 2023 | 4.300 | Q1 |
| 2024 | 5.400 | Q1 |
| 2025 | 7.700 | Q1 |
WORLD JOURNAL OF GASTROENTEROLOGY 最新收录文献
-
1. Optimal cannabinoid-terpene combination ratios suppress mutagenicity of gastric reflux in normal and metaplastic esophageal cells.
PMID:日期:2026-04-14Esophageal adenocarcinoma (EAC) frequently arises from chronic exposure to acid and bile reflux, with secondary bile acids, such as deoxycholic acid (DCA), contributing to its pathogenesis through mechanisms involving reactive oxygen species (ROS), oxidative DNA damage, and resistance to apoptosis. The human endocannabinoid system (ECS) regulates diverse anti-inflammatory, antioxidant, and analgesic pathways implicated in disease modulation and may counteract the harmful effects of gastroesophageal reflux. Despite its therapeutic promise, effective pharmacological activation of the ECS remains challenging. To evaluate whether specific cannabinoid-terpene combinations targeting the ECS could attenuate the mutagenic and cytotoxic effects of bile acid-induced stress in esophageal cell models, and to assess the clinical significance of ECS-related protein receptors in the progression of EAC. Human esophageal epithelial cells exposed to DCA, as well as a Barrett's esophagus cell line subjected to low potential of hydrogen and a bile acid cocktail, were treated with various ratios of phyto-cannabinoids and terpenes. Endpoints included DNA damage, mitochondrial membrane potential, and ROS production to identify optimal compound combinations. Expression of ECS-related receptor proteins in clinical samples was assessed by immunohistochemistry. A 1:5 ratio of cannabigerol to phytol significantly reduced DCA-induced DNA damage, preserved mitochondrial membrane potential, and decreased ROS levels. This combination also promoted apoptosis in damaged cells and reduced mutagenicity. Analysis of patient samples demonstrated that expression of the ECS-associated receptor protein CB1 correlated with EAC progression, indicating a broader clinical role for ECS modulation in cancer prevention. Modulation of the ECS using systematically selected cannabinoid-terpene ratios can attenuate bile acid-induced esophageal damage and may reduce carcinogenic progression. These findings support further studies and raise the possibility of expanding cannabinoid-terpene therapeutics to other diseases with comparable pathogenic mechanisms.
-
2. Mechanisms and therapeutic potential of traditional Chinese medicine for inflammatory bowel disease.
2. 中医药治疗炎症性肠病的机制和治疗潜力PMID:日期:2026-03-14Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory disorder of the intestine with a rising global incidence that significantly impairs patients' quality of life. Although modern medical therapies can provide short-term symptom relief, they are often limited by dependence on medication and considerable adverse effects. Traditional Chinese medicine (TCM) has demonstrated longstanding clinical efficacy and preclinical advantages in IBD management, yet systematic summaries and in-depth mechanistic insights remain insufficient. This minireview explores recent advances in the mechanistic research of TCM for IBD to inform alternative therapeutic strategies. A systematic literature search was conducted using databases including PubMed, Science Citation Index Expanded, and China National Knowledge Infrastructure to synthesize current evidence, focusing on literature published between 2023 and 2025. Findings reveal that TCM exerts therapeutic effects through holistic, multicomponent, multi-target, and multi-pathway regulation. Key mechanisms involve modulation of inflammatory signaling pathways, immune homeostasis, gut microbiota composition, intestinal barrier integrity, autophagy, metabolic functions, gene expression, and synergistic multi-target therapy. Despite existing research limitations, the evolution from empirical herbal use toward modern scientific understanding promises to accelerate the modernization and global integration of TCM. This minireview provides foundational insights for future research and clinical practice, with the potential to benefit IBD patients worldwide.
-
3. Lessons from extended induction and practical evidence for improving tofacitinib therapy in ulcerative colitis.
3. 扩大诱导的经验教训和改进托法替尼治疗溃疡性结肠炎的实践证据PMID:日期:2026-03-07With the introduction of Janus kinase inhibitors like tofacitinib, the treatment landscape for ulcerative colitis (UC) is changing quickly. Response heterogeneity is still a significant clinical challenge in spite of its quick onset and oral convenience. Extending tofacitinib induction beyond the standard eight weeks can produce significant benefits in a subset of patients without sacrificing safety, according to evidence from pivotal trials and real-world studies. We review recent real-world evidence, highlight lessons learnt from extended induction therapy, and present a practical framework to help guide tailored treatment decisions in this editorial. After 16 weeks of prolonged induction, more than half of patients with moderate-to-severe UC experienced remission, with durable persistence and favorable safety, according to a multicenter 52-week real-world study published in this issue of the . Crucially, outcomes and maintenance dosing were impacted by modifiable factors like smoking and biologic exposure. Mechanistic findings support a response-guided rather than fixed-duration induction paradigm by indicating that immune kinetics, mucosal healing rates, and previous biologic exposure may account for delayed responses. An effective, patient-centered strategy that could maximize tofacitinib's therapeutic potential and assist in guiding refractory UC patients towards long-term remission is extended induction.
-
4. {"_":"Small animal machine perfusion of the liver: A comprehensive literature review.","i":["ex vivo"]}
PMID:日期:2026-03-07Liver transplantation is the only treatment for acute and chronic liver failure, but the global organ shortage has increased reliance on extended criteria donor livers, which are more susceptible to ischemia-reperfusion injury. While static cold storage is standard, these grafts often require improved preservation strategies. To summarize the current state of small animal liver machine perfusion (MP), highlight variability in protocols, and emphasize the need for standardization to guide future research. A comprehensive literature search of PubMed was conducted to identify studies on small animal (rat and mouse) liver MP. Only English-language animal studies were included, with no restrictions on publication date. Relevant full-text articles were reviewed, and reference lists were screened to ensure completeness. Small animal liver MP provides a cost-effective model to explore dynamic preservation strategies. Rat perfusion studies face challenges including dual-vessel perfusion, maintaining physiological perfusate volumes, and lack of standardized protocols. Open- and closed-circuit setups have distinct advantages and limitations, and experimental designs vary widely across studies. This review illustrates the wide variability in small animal liver MP protocols and underscores the urgent need for standardization. Addressing these inconsistencies will enhance reproducibility, facilitate comparison across studies, and support the development of optimized liver preservation strategies.
-
5. {"_":"Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics biosimilars.","i":["vs"]}
PMID:日期:2026-03-07Biologic therapies, including anti-tumor necrosis factor agents, have significantly improved the management of inflammatory bowel disease (IBD). However, their high cost can limit patient access. Biosimilars are a more affordable option than originator biologics and offer potential for improved accessibility, though real-world evidence comparing their effectiveness remains limited. To describe real-world, comparative outcomes of IBD patients taking biologics and biosimilars, focusing on remission and healthcare use. We used data from a multicenter registry-based cohort, which includes participants from six Canadian IBD clinical centers. Adults with ulcerative colitis or Crohn's disease who initiated biosimilar, or originator formulations of infliximab or adalimumab were included. The primary outcome was clinical remission; secondary outcomes included hospitalizations and emergency department (ED) visits. Kaplan-Meier survival analyses and multivariable Cox regression models were used to assess time to these outcomes, adjusting for disease activity, treatment history, and demographic characteristics. A total of 258 individuals were analyzed (192 biosimilar initiators and 66 originator users). The median time to remission was similar between biosimilars (12.2 months) and originators (12.8 months). We did not detect difference in the likelihood of achieving remission when comparing biosimilar and originator treatments (adjusted hazard ratio: 1.49; 95% confidence interval: 0.96-2.32). Hospitalization and ED visit rates were also comparable. Corticosteroid use and prior hospitalizations were associated with increased hospitalization risk. This study suggests biosimilars and originators have similar remission, ED visits, and hospitalization in IBD. This reinforces confidence in their equivalence, improving access while supporting healthcare system sustainability.
-
6. Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection.
6. 慢性乙型肝炎感染患者代谢功能障碍相关脂肪性肝炎的诊断和治疗PMID:日期:2026-03-07Chronic hepatitis B (CHB) infection is a global public health burden, affecting over 250 million persons globally, and is associated with substantial morbidity and mortality due to cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Metabolic syndrome and metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly common co-morbidity among patients with CHB, affecting an estimated 25%-40% of individuals. The physiologic and clinical impact of co-existing CHB and metabolic syndrome and/or MASLD [met-hepatitis B virus (HBV)] is poorly understood, although recent data suggest important associations with poorer antiviral response and clinical outcomes. This review summarizes current and emerging evidence addressing this relationship, and outline recommendations for the diagnosis, risk stratification, staging, and management of Met-HBV.
-
7. Simultaneous treatment of concomitant achalasia coexisting with epiphrenic diverticulum: The practice of submucosal tunneling technique.
PMID:日期:2026-03-07Esophageal epiphrenic diverticulum (ED) often occurs in patients with esophageal motility disorders, and its incidence rate is approximately 3%-7% in achalasia (AC). A distinct septum has been observed in some patients with AC coexisting with ED during gastroscopy. Digestive endoscopic tunnel technique has emerged as a promising therapeutic approach for these patients. To evaluate the therapeutic effectiveness of specific treatment methods for ED with septum (ED + S) or ED without septum (ED - S) in AC patients. This retrospective cohort study included 31 patients with AC and esophageal diverticula (21 patients with septum and 10 patients without septum) between January 2016 and January 2025. In ED + S group, submucosal tunneling myotomy combined with diverticular septotomy was performed, while patients in the ED - S group underwent submucosal myotomy alone. The Eckardt scores before and after surgery were compared to evaluate symptom relief and clinical success. The Gastroesophageal Reflux Disease Questionnaire (GERD-Q) score and gastroscopy findings were used to evaluate postoperative gastroesophageal reflux. The corresponding operation steps were completed in both groups, with a technical success rate of 100%. We successfully followed up with 18 and 10 patients in the ED + S and ED - S group, with a median follow-up period of 2.5 years and 3.0 years, respectively. The postoperative Eckardt scores [median (interquartile range)] were significantly lower in both groups compared with preoperative scores [ED + S group: 6.0 (4.0-8.0) 0 (0-2.0), < 0.05; ED - S group: 6.0 (3.75-8.25) 1.0 (0-3.0), < 0.05]. The clinical success rates (Eckardt score ≤ 3) were 88.9% and 90.0%, respectively. The GERD-Q score was used to evaluate postoperative gastroesophageal reflux, and 3 patients (3/18, 16.7%) in ED + S group and 2 patients (2/10, 20%) in ED - S group experienced symptomatic reflux (GERD-Q score ≥ 8). In AC patients with ED + S, submucosal tunneling myotomy with diverticular septotomy can achieve good therapeutic effects. When there is no obvious septum, submucosal tunneling myotomy is an effective method.
-
8. {"_":"Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease peroxisome proliferator-activated receptor alpha pathway activation.","i":["via"]}
8. {"_":"联合消脂膏通过激活过氧化物酶体增殖物激活受体α通路改善代谢功能障碍相关脂肪性肝病。","i":["via"]}PMID:日期:2026-03-07Lianhe Xiaozhi ointment (LXO), an innovative formulation derived from the classic Huanglian Wendan decoction, has been granted a national invention patent. With increasing years of clinical expertise within the Jiangsu Province Hospital of Chinese Medicine in China, LXO has become increasingly recognized as a potent remedy for metabolic disorders, particularly metabolic dysfunction-associated steatotic liver disease (MASLD). To date, specific bioactive components and underlying mechanisms remain unclear. To determine the bioactive components of LXO and clarify its mechanisms of action relevant to management of MASLD. We used ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry and network pharmacology approaches to systematically determine the key bioactive components of LXO and elucidate biological pathways modulated in the treatment of MASLD. Critical signaling pathways were also elucidated hepatic transcriptomic analysis, and an exhaustive and rigorous exploration of the therapeutic efficacy and underlying mechanisms of LXO in MASLD was conducted a combination of and high-fat model experiments. Network pharmacology analysis revealed six pivotal bioactive components within LXO that collectively serve as the cornerstone for their efficacy against MASLD. LXO exerts multiple therapeutic effects, including weight gain retardation, amelioration of glucose and lipid metabolism disturbances, liver injury mitigation, hepatic inflammation alleviation, and correction of gut microbiota disorders. Multiple platform analyses, including hepatic transcriptomics, quantitative real-time polymerase chain reaction, and western blotting, confirmed that LXO induces peroxisome proliferator-activated receptor alpha (PPARα) transcriptional activation in the liver. studies confirmed that a PPARα antagonist markedly diminishes the lipid-lowering capacity of LXO. Collectively, our findings suggest that LXO exerts therapeutic effects on high-fat diet-induced MASLD at least in part PPARα pathway activation.
-
9. Perioperative serum carcinoembryonic antigen: Powerful marker for prognostic prediction and adjuvant chemotherapy decision-making in patients with stage II and III colorectal cancer.
PMID:日期:2026-03-07Assessment of the prognosis, follow-up monitoring, and adjuvant treatment decision-making for patients with stage II and III colorectal cancer (CRC) are controversial, as CRC harbors tremendous heterogeneity. Carcinoembryonic antigen (CEA) is an important tumor marker; however, the use of this marker in the management of CRC has not garnered adequate attention. To determine the significance of perioperative CEA levels in prognostic stratification and treatment decision making to provide personalized diagnosis and treatment for patients with stage II and III CRC. Patients in the training and validation cohorts were diagnosed with primary stage II or III CRC. Preoperative CEA (pre-CEA) and postoperative CEA (post-CEA) were collectively defined as perioperative CEA. Kaplan-Meier (K-M) survival analyses were used to describe patient survival. Cox stepwise regression analysis based on Akaike information criterion was used to determine the prognostic value of clinicopathological characteristics. Nomograms were developed to predict the probability of overall survival (OS) and disease-free survival (DFS). Annual hazard curves and pie charts were used to demonstrate the features of recurrence or metastasis. Differences were considered statistically significant at < 0.05. A total of 2496 and 1293 patients were included in the training and validation cohorts, respectively. K-M analysis indicated that patients with elevated perioperative CEA had poorer OS and DFS, with post-CEA being an independent prognostic factor for OS and DFS. Nomograms based on factors associated with prognosis were constructed, which showed good predictive ability for 3-, 5-, and 7-year OS and DFS. Patients with elevated perioperative CEA were more likely to have recurrence or metastasis, and the period of the second year after surgery was the peak time of recurrence or metastasis. OS and DFS were significantly worse in patients without adjuvant chemotherapy when they had elevated perioperative CEA. Adjuvant chemotherapy could significantly improve the OS of patients with elevated perioperative CEA. Patients with elevated post-CEA who received XELOX could achieve better OS and DFS. Perioperative CEA demonstrate sufficient sensitivity in the prognosis prediction and follow-up of patients with stage II and III CRC. Furthermore, perioperative CEA, especially post-CEA, show promise in guiding adjuvant chemotherapy, suggesting potential for further study.
-
10. Research progress of plant-derived chemical compounds for overcoming pancreatic cancer drug resistance.
PMID:日期:2026-03-07Pancreatic cancer, a highly malignant gastrointestinal tumor, has a five-year survival rate of only 10%. With the increasing aging population, its incidence is rising across East Asia, North America, and Europe. Chemotherapy remains a basic strategy of the current treatment regimen for pancreatic cancer. However, the development of multidrug resistance poses a significant challenge, drastically reducing the efficacy of chemotherapy agents. The mechanisms underlying resistance in pancreatic cancer remain incompletely understood. To overcome this obstacle, scientists are dedicated to discovering new therapeutic strategies and addressing the issue of resistance. Plant-derived chemicals played essential roles in many documented ancient cultures, such as those in ancient China, ancient Egypt, ancient India, and ancient Babylon. Many modern medications are derived from plants, including paclitaxel, a widely used and effective chemotherapy agent originally derived from the Pacific yew tree. Although the development of plant-based compounds for cancer treatment is still under development, these compounds offer several advantages, including a long history of safe use, fewer side effects, lower costs, and improved patient acceptance. Recent studies have shown that plant-derived chemicals can significantly inhibit tumor cell proliferation and reversal drug resistance. Clinical trials have demonstrated promising therapeutic effects of these compounds in cancer treatment. This review summarizes recent research on the role of plant-derived compounds in overcoming drug resistance in pancreatic cancer. It provides insights into the mechanisms of drug resistance and highlights the potential of plant-based compounds as alternative therapeutic strategies. Considering the limitations of current therapies and the growing issue of drug resistance, plant-derived compounds offer a promising direction for enhancing treatment outcomes. This review aims to inform future research and promote the development of more effective, safer, and patient-friendly treatment options for pancreatic cancer.